Lessons from the Type II Family of G-Protein-Coupled Recepton 12 13 14 I5 16 17 18 19 20 21 22 23 Nikitenko, L. L., Smith, D. M., Hague, zyxwvutsr S., Wilson, C. R., Bicknell, R. and Rees, M. C. P. (2002) Trends Pharmacol. Sci. 23, I0 I - I03 Champion, H. C., Nussdorfer, G. G. and Kadowitz, P. J. ( 1999) Regul. Pept. 85, 1-8 Miller, M. J., Martinez, A., Unsworth, E. J,, Thiele, C. J., Moody, T. W., Elsasser, T. and Cuttitta, F. ( 1996) J. Biol. Chem. 271, 23345-2335 I Lin, H. Y., Hams, T. L., Flannery, M. S., Aruffo, A,, Kaji, zyxwvutsrq E. H., Gorn, A., Kolakowski, L. F., Lodish, H. F. and Goldring, 5. R. ( I99 I ) Science 254, 1022- I024 Gether, U. (2000) Endocr. Rev. 2 I, 90- I I 3 Njuki, F., Nicholl, C. G., Howard, A., Mak J. C., Barnes, P. J,, Girgis, S. I. and Legon, S. ( 1993) Clin. Sci. 85, 385-388 Fluhmann, B., MuK R., Hunziker, W., Fischer, J. A. and Born, W. (I 995) Biochem. Biophys. Res. Commun. 206, 34 1-347 McLatchie, L. M., Fraser, N. J., Main, M. J,, Wise, A,, Brown, J., Thompson, N., Solari, R., Lee, M. G. and Foord, 5. M. (I 998) Nature (London) 393, 333-339 Chakravarty, P., Suthar, T., Coppock, H. A,, Nicholl, C. G., Bloom, 5. R., Legon, 5. and Smith, D. M. (2000) Br. J. Pharmacol. zyxwvutsrq 130, I 89- I95 Owji, A. A., Gardiner, J. V., Upton, P. D., Mahmoodi, M., Ghatei, M. A., Bloom, 5. R. and Smith, D. M. (I 996) J. Neurochem. 67,2 172-2 I79 Hilairet, S., Foord, 5. M., Marshall, F. H. and Bouvier, M. (200 I) J. Biol. Chem. 276,29575-2958 I Hay, D. L. and Smith, D. M. (2001) Peptides 22, 1753- I763 24 25 26 27 28 29 30 31 32 33 Buhlmann, N., Leuthauser, K., Muff, R., Fischer, J. A. and Born, W. ( 1999) Endocrinology 140, 2883-2890 Kamitani, S., Asakawa, M., Shimekake, Y., Kuwasako, K., Nakahara, K. and Sakata, T. (I 999) FEBS Lett. 448, Coppock, H. A., Owji, A. A., Bloom, 5. R. and Smith, D. M. (I 996) Biochem. J. 3 I8,24 1-245 Withers, D. J., Coppock H. A,, Seufferiein, T., Smith, D. M., Bloom, 5. R. and Rozengurt, E. (I 996) FEBS Lett. 378, Coppock, H. A., Owji, A. A,, Austin, C., Upton, P. D., Jackson, M. L., Gardiner, J. V., Ghatei, M. A,, Bloom, 5. R. and Smith, D. M. (I 999) Biochem. J. 338, 5-22 Shimekake, Y., Nagata, K., Ohta, S., Kambayashi, Y., Teraoka, H., Kitamura, K., Eto, T., Kangawa, K. and Matsuo, H. J. (I 995) J. Biol. Chem. 270, 44 12-44 I 7 Kuwasako, K., Shimekake, Y., Masuda, M., Nakahara, K., Yoshida, T., Kitaura, M., Kitamura, K., Eto, T. and Sakata, T. (2000) J. Biol. Chem. 275, 29602-29609 Kuwasako, K., Kitarnura, K., Ito, K., Uemura, T., Yanagita, Y., Kato, J., Sakata, T. and Eto, T. (2001) J. Biol. Chem. 276, 4945949465 Hay, D. L. and Smith, D. M. (200 I) Trends Pharmacol. Sci. 22, 57-59 Doods, H., Hallemayer, G., Wu, D., Entzeroth, M., Rudolf, K., Engel, W. and Eberlein, W. (2000) Br. J. Pharmacol. 129, 42M23 I 1 1 - 1 14 83-87 Received I3 March 2002 zyxwvu Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations M. Waelbroeck', 1. Perret, P. Vertongen, M. Van Craenenbroeck and P. Robberecht Department of Biochemistry and Nutrition, School of Medicine, Univenite Libre de Bruxelles, Bit G/E, CP 6 I I, 808 route de Lennik, B- I070 Brussels, Belgium Abstract We have identified two basic residues that are important for the recognition of secretin and vasoactive intestinal peptide (VIP) by their re- spective receptors. These two peptides containing an Asp residue at position 3 interacted with an arginine residue in transmembrane helix 2 (TM2) of the receptor, and the lysine residue in extra- cellular loop 1 (ECL1) stabilized the active receptor conformation induced by the ligand. The glucagon receptor possesses a Lys instead of an Arg in TM2, and an Ile instead of Lys in ECLl ; it markedly prefers a Gln side chain in position 3 of the ligand. Our results suggested that, in the wild-type receptor, the Ile side chain prevented access to the TM2 Lys side chain, but oriented the glucagon Gln3side chain to its proper binding site. In the double mutant, the ECLl Lys allowed an interaction between negatively charged residues in position 3 of glucagon and the TM2 Arg, resulting in efficient receptor activation by [Asp3]glucagon as well as by glucagon. ~ ~~~ Key words: extracellular loop, secretin receptor family, trans- membrane helix, VIP. Abbreviations used: ECLI, extracellular loop I (etc.); GLP, glucagon-like peptide; PACAP, pituitary adenylate cyclase- activating polypeptide: TM I, transmembrane helix I (etc.); VIP, vasoactive intestinal peptide. 'To whom correspondence should be addressed (e-mail mawaelbr@ulb.ac.be). Introduction Glucagon, secretin and vasoactive intestinal pep- tide (VIP) belong to the glucagon superfamily of peptide hormones, which all have a histidine residue in position 1 and phenylalanine in position zy 6 [l]. They stimulate adenylate cyclase activity 43 7 zyxwvu 0 2002 Biochemical Society